FDA Approved: GAMIFANT — Supplemental Application (Swedish Orphan Biovitrum AB (publ))

View source ↗

Summary

FDA approved a supplemental application for GAMIFANT (emapalumab-lzsg) from Swedish Orphan Biovitrum AB (publ), updating its labeling/indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• GAMIFANT (emapalumab-lzsg)

Snippet

SUPPL AP for GAMIFANT (EMAPALUMAB-LZSG)